In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine ...

A federal court dismissed a journalist’s claims against Pfizer executives and a member of the former Biden Administration for ...

Pfizer (PFE) concluded the recent trading session at $25.35, signifying a -1.17% move from its prior day's close.

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of ...

A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

SCHD underperformed the S&P 500 in 2025 but remains highly attractive due to its strong risk-reward profile and dividend ...

The World Health Organization (WHO) has validated Senegal as having eliminated trachoma as a public health problem. Senegal ...

Aurobindo Pharma has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement ...